• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    China Jo-Jo Drugstores Announced Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    6/16/23 4:29:00 PM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CJJD alert in real time by email

    HANGZHOU, China, June 16, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that on June 15, 2023, the Company has received a notification letter from Nasdaq Listing Qualifications Department ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement from May 3, 2023 through June 14, 2023. As set forth in Nasdaq Listing Rules 5550(a)(2) ("Nasdaq Listing Rule"), it requires that the closing bid price for the Company's ordinary shares listed on Nasdaq be maintained at a minimum of US$1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency.

    The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq.

    In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until December 12, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time during this 180 day period, or before December 12, 2023, the closing bid price of the Company's ordinary shares is at least US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by December 12, 2023, the Company may be eligible for additional time to regain compliance, if the Company provide written notice of its intention to cure the deficiency during the second compliance period and is in compliance with the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market.

    The Company intends to monitor the closing bid price of its ordinary shares between now and December 12, 2023. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements towards  the end of the first compliance period, the Company's Board of Directors will consider options that may be available to achieve compliance.

    About China Jo-Jo Drugstores, Inc.

    China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.

    Forward-Looking Statements

    This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.

    For more information, please contact:

    Company Contact: 

    Frank Zhao

    Chief Financial Officer

    +86-571-88077108

    [email protected]

    Investor Relations Contact:

    Tina Xiao

    Ascent Investor Relations LLC

    +1-917-609-0333

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/china-jo-jo-drugstores-announced-receipt-of-nasdaq-notification-regarding-minimum-bid-price-deficiency-301853489.html

    SOURCE China Jo-Jo Drugstores, Inc.

    Get the next $CJJD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CJJD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CJJD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by China Jo-Jo Drugstores Inc.

    SCHEDULE 13D/A - Ridgetech Inc. (0001856084) (Subject)

    3/4/25 4:50:18 PM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by China Jo-Jo Drugstores Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    3/3/25 9:41:03 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by China Jo-Jo Drugstores Inc.

    6-K - China Jo-Jo Drugstores, Inc. (0001856084) (Filer)

    2/3/25 8:30:06 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CJJD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ridgetech, Inc. Announces 1-for-150 Reverse Share Split

    HANGZHOU, China, April 3, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (NASDAQ:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ordinary shares ("Ordinary Shares") effective Tuesday, April 7, 2026 at 5:00 p.m. Eastern Time, with trading to begin on a split‑adjusted basis at the market open on the next trading day. Trading in the Ordinary Shares will continue on the Nasdaq Capital Market under the symbol "RDGT." The new CUSIP number for the Ordinary Shares following the reverse share split is G2124G 203. As of April 2, 2026, the

    4/3/26 12:00:00 PM ET
    $CJJD
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth

    HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has entered into definitive agreements for a strategic restructuring initiative to transition into an asset-light, wholesale-focused company, streamlining operations and enhancing profitability. The restructuring involved two major transactions (the "Transactions"): Acquisition transaction: The acquisition of Allright (Hangzhou) Internet Technology Co. Ltd. ("Allright"), a fast-growing company engaged in

    2/3/25 8:00:00 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    China Jo-Jo Drugstores Reports Fiscal Year 2024 Financial Results

    HANGZHOU, China, July 30, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2024. Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased to present our financial performance for fiscal year 2024, which reflects our commitment to maintaining a resilient business model in a dynamic market. We achieved a significant 42.1% revenue growth in our wholesale business, a result of our dedicated efforts in target

    7/30/24 9:00:00 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CJJD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by China Jo-Jo Drugstores Inc.

    SC 13D/A - China Jo-Jo Drugstores, Inc. (0001856084) (Subject)

    11/14/24 4:15:11 PM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by China Jo-Jo Drugstores Inc.

    SC 13D/A - China Jo-Jo Drugstores, Inc. (0001856084) (Subject)

    9/3/24 8:50:20 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by China Jo-Jo Drugstores Inc. (Amendment)

    SC 13D/A - China Jo-Jo Drugstores, Inc. (0001856084) (Subject)

    4/16/24 4:30:11 PM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CJJD
    Leadership Updates

    Live Leadership Updates

    View All

    China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth

    HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has entered into definitive agreements for a strategic restructuring initiative to transition into an asset-light, wholesale-focused company, streamlining operations and enhancing profitability. The restructuring involved two major transactions (the "Transactions"): Acquisition transaction: The acquisition of Allright (Hangzhou) Internet Technology Co. Ltd. ("Allright"), a fast-growing company engaged in

    2/3/25 8:00:00 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CJJD
    Financials

    Live finance-specific insights

    View All

    China Jo-Jo Drugstores Reports Fiscal Year 2024 Financial Results

    HANGZHOU, China, July 30, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2024. Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased to present our financial performance for fiscal year 2024, which reflects our commitment to maintaining a resilient business model in a dynamic market. We achieved a significant 42.1% revenue growth in our wholesale business, a result of our dedicated efforts in target

    7/30/24 9:00:00 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    China Jo-Jo Drugstores Reports Fiscal Year 2022 Financial Results

    HANGZHOU, China, July 28, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2022. Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased with our fiscal year 2022 financial results, which reflect our continued growth momentum that we have achieved overall improvement across all key financial metrics. Compared with fiscal year 2021, our total revenue and gross profit increased by 23.5% and 24.9%, respecti

    7/28/22 9:00:00 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    China Jo-Jo Drugstores Reports First Half of Fiscal Year 2022 Financial Results

    HANGZHOU, China, Jan. 21, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products, and healthcare provider in China, today announced its financial results for the first half of fiscal year 2022 ended September 30, 2021. Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased to have delivered a solid performance during the first half of fiscal year 2022 as we navigate through a challenging operating environment affected by multiple COVID-19 surges. We achieved record revenue of $78.48 million, up 26.8% from the same

    1/21/22 9:00:00 AM ET
    $CJJD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples